To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer

Sponsor

GenMont Biotech Incorporation (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT06039644

Collaborator

Mackay Memorial Hospital (Other)

100

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer patients. This study is designed to explore after consumption of probiotics of lactobacillus composite strain powder sachets for 6 months in breast cancer chemotherapy, and whether the improvement of meliorate the side effects, further assists patients completing the chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer	Dietary Supplement: Probiotic Other: Placebo	N/A

Detailed Description

In 2020, the incidence rate of women's breast cancer in Taiwan was up to 82.1% . The death rate increased to 16%; in 2021, the ranking rose to no.3, and the death rate grew up to 24.6%. In the decades, breast cancer gradually becomes the dominant malignant women's cancer in Taiwan. Besides the lumpectomy, chemotherapy is one of the dominant and important treatments for breast cancer. Beyond the effects of chemotherapy, several side effects rise up. The most common chemotherapy are anthracyclin drugs (doxorubicin and epirubicin) and taxane (docetaxel and paclitaxel ). There are common side effects including neutropenia, hair loss, vomiting, diarrhea, stomatitis, mucositis, peripheral neuropathy, dermatitis, nephrotoxicity, and hepatotoxicity. Currently, most treatments for chemotherapy-induced side effects are symptomatic treatment, but there is no good solution to prevent it.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Parallel Assignment, Randomized Controlled TrialParallel Assignment, Randomized Controlled Trial

Masking:

Double (Participant, Investigator)

Primary Purpose:

Supportive Care

Official Title:

To Evaluate the Efficacy of Probiotics in Improvement and Prevention of Chemotherapy Associated Side Effectes in Patients With the Breast Cancer

Anticipated Study Start Date :

Nov 1, 2023

Anticipated Primary Completion Date :

Nov 1, 2025

Anticipated Study Completion Date :

Dec 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Probiotic group Subjects received two probiotic sachets per day	Dietary Supplement: Probiotic Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive). Other Names: Test group
Placebo Comparator: Placebo group Subjects received two placebo sachets per day	Other: Placebo Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin. Other Names: Control group

Arm

Intervention/Treatment

Experimental: Probiotic group

Subjects received two probiotic sachets per day

Dietary Supplement: Probiotic

Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).

Other Names:

Test group

Placebo Comparator: Placebo group

Subjects received two placebo sachets per day

Other: Placebo

Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.

Other Names:

Control group

Outcome Measures

Primary Outcome Measures

Change from 12 weeks in the chemotherapy associated side-effects questionnaire at 24 weeks [24 weeks]
The questionnaire will finished to record the side effects, including nausea, vomiting, diarrhea, stomatitis, peripheral neuropathy, skin rashes, and hand-food syndrome before and after the treatment.

Secondary Outcome Measures

Change from 12 weeks in self-record of the FACT-G questionnaire (The Functional Assessment of Cancer Therapy - General; Version 4) at 24 weeks [24 weeks]
The FACT-G questionnaire will record the quality of life by subjects at 12-weeks and-24 weeks. There are 4 domains of quality of life will be measured, including physical well-being, social/family well-being, emotional well-being, functional well-being. All domains will sum as total score of 108, and each domain will also evaluated.
Variability in BMI (Body Mass Index) [24 weeks]
BMI will calculated with weight and height combined in kg/m^2. Measured every visit (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Change from baseline in levels of hs-CRP (high-sensitivity C-Reactive Protein) in mg/dL at 12 weeks [12 weeks]
Blood samples will collected to examine the variation of hs-CRP from baseline at 12 weeks.
Change from baseline in levels of hs-CRP (high-sensitivity C-Reactive Protein) in mg/dL at 24 weeks [24 weeks]
Blood samples will collected to examine the variation of hs-CRP from baseline at 24 weeks.
Change from baseline in levels of IL-6 (Interleukin-6) in pg/mL at 12 weeks [12 weeks]
Blood samples will collected to examine the variation of IL-6 from baseline at 12 weeks.
Change from baseline in levels of IL-6 (Interleukin-6) in pg/mL at 24 weeks [24 weeks]
Blood samples will collected to examine the variation of IL-6 from baseline at 24 weeks.
Change from baseline in levels of IL-10 (Interleukin-10) in pg/mL at 12 weeks [12 weeks]
Blood samples will collected to examine the variation of IL-10 from baseline at 12 weeks.
Change from baseline in levels of IL-10 (Interleukin-10) in pg/mL at 24 weeks [24 weeks]
Blood samples will collected to examine the variation of IL-10 from baseline at 24 weeks.
Change from baseline in levels of TNF-α (Tumor Necrosis Factor-α) in pg/mL at 12 weeks [12 weeks]
Blood samples will collected to examine the variation of TNF-α from baseline at 12 weeks.
Change from baseline in levels of TNF-α (Tumor Necrosis Factor-α) in pg/mL at 24 weeks [24 weeks]
Blood samples will collected to examine the variation of TNF-α from baseline at 24 weeks.
Change from baseline in gut microbiome at 12 weeks [12 weeks]
Fecal sample will collected to extract DNA from the intestinal microbiota to examine the variations of gut microbiome from baseline at 12 weeks by NGS (Next Generation Sequencing) analysis.
Change from baseline in gut microbiome at 24 weeks [24 weeks]
Fecal sample will collected to extract DNA from the intestinal microbiota to examine the variations of gut microbiome from baseline at 24 weeks by NGS (Next Generation Sequencing) analysis.
Variability in levels of ALT (Alanine Aminotransferase) in IU/L [24 weeks]
ALT levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of AST (Aspartate Aminotransferase) in IU/L [24 weeks]
AST levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of Creatinine in mg/dL [24 weeks]
Creatinine levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of Hb (Hemoglobin) in g/dL [24 weeks]
Hb levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of RBC (Red Blood Cell count) in 10^6/μL [24 weeks]
RBC levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of Ht (Hematocrite) in % [24 weeks]
Ht levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of WBC(White Blood Cell count) in 10^3/μL [24 weeks]
WBC levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of MCV (Mean Corpuscular Volume) in fL [24 weeks]
MCV levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of MCH (Mean Corpuscular Haemoglobin) in Pg [24 weeks]
MCH levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of MCHC (Mean Corpuscular Haemoglobin Concentration) in g/dL [24 weeks]
MCHC levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)
Variability in levels of ANC (Absolute Neutrophil Count) in mm^3 [24 weeks]
Total neutrophils and WBC collected from routine medical records at each visit to calculate ANC levels. (week 0. 3. 6. 9. 12. 15. 18. 21. 24) ANC is calculated as 10 x WBC count in 1000s x (%Segment neutrophils + % bands neutrophils).
Variability in levels of platelet in 10^3/μL [24 weeks]
Platelet levels will obtained from routine medical records every visit. (week 0. 3. 6. 9. 12. 15. 18. 21. 24)

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Stage I-III breast patients using anthracycline-based and taxane-based chemotherapy (not limited before or after chemotherapy/surgery)
BMI > 18 kg/m^2
Age between 20 and 80 years old
Patients judged by physicians to participate in this trial and who are willing

Exclusion Criteria:

Pregnant or lactating female patients
Patients with bariatric surgery, gastrointestinal resections, Crohn's disease, celiac disease
BMI < 18 kg/m^2
Patient who have severe allergy to soybeans or peanuts
Those who are under 20 years old or over 80 years old